Amundi Increases Stake in Danaher Corporation $DHR

Key Points

• Amundi increased its stake in Danaher Corporation by 1.2% during the first quarter, owning approximately 3,053,611 shares valued at $605 million.
• Wall Street analysts generally hold a positive outlook for Danaher, with a consensus price target of $246.35 and the majority rating its stock as a "Moderate Buy."
• Insider trading activity showed Director Teri List selling 2,778 shares, reducing her position by 11.81%, highlighting ongoing shifts in shareholder activity.

Amundi raised its position in Danaher Corporation (NYSE:DHR - Free Report) by 1.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,053,611 shares of the conglomerate's stock after purchasing an additional 35,457 shares during the period. Amundi owned 0.43% of Danaher worth $605,153,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Heck Capital Advisors LLC bought a new position in Danaher in the 4th quarter valued at $27,000. GHP Investment Advisors Inc. lifted its holdings in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after acquiring an additional 99 shares during the last quarter. Sierra Ocean LLC lifted its holdings in shares of Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after acquiring an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC bought a new stake in shares of Danaher during the 1st quarter worth $31,000. Finally, Dunhill Financial LLC lifted its holdings in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after acquiring an additional 67 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Activity

In other Danaher news, Director Teri List sold 2,778 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.10% of the company's stock.

Danaher Trading Up 0.6%

Shares of DHR stock traded up $1.29 during mid-day trading on Friday, reaching $200.32. The stock had a trading volume of 2,837,584 shares, compared to its average volume of 2,859,442. The stock's 50-day moving average price is $201.93 and its two-hundred day moving average price is $199.41. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The firm has a market capitalization of $143.44 billion, a PE ratio of 42.62, a price-to-earnings-growth ratio of 2.78 and a beta of 0.75. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter in the previous year, the company earned $1.72 earnings per share. The company's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research analyst reports. Wells Fargo & Company dropped their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Barclays reaffirmed an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Evercore ISI dropped their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Finally, Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a research note on Friday, July 11th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $246.35.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.